Skip to content
Modern Reel Review

America and Britain Reach Duty-Free Deal on Medicines.

Pharmaceutical trade between the United States and United Kingdom
Conceptual image of medicine shipments.

Britain and America have announced a important trade agreement that will ensure zero levies on British drug exports going into the US market.

Key Provisions of the Deal

Under the terms of the agreement, the UK has agreed to boost funding on drugs through the National Health Service (NHS). This commitment secures that duties on these key exports will stay at nothing for a duration of 36 months.

This development comes after previous threats to significantly raise import taxes on patented pharmaceutical products, with figures discussed up to double the cost.

"This deal with the UK strengthens the global environment for new treatments and introduces much-needed fairness to American-British drug exports," a release declared.

Economic Importance

Medicines are one of the Britain's biggest export categories to the America, which is easily the largest buyer for major UK drugmakers.

Trade data show that in the one-year period leading up to last September, the UK sold drugs valued at billions to the US. This amount made up nearly one-fifth of total UK exports in that span.

"This guarantee safeguards employment, increases capital expenditure and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.

Key British Pledges

The agreement involves several specific commitments from the United Kingdom:

  • Price Threshold Increase: The UK will lift the price threshold at which it considers new medicines to be too expensive by a quarter.
  • Higher Drug Budget: There is a goal to double total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
  • Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded 20%.

Recent Tensions

This agreement follows a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.

These tensions were heightened by assertions that US customers were charged a premium for the identical medicines than consumers in the UK and Europe.

Over the last 18 months, several large manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been pledged toward American operations.

A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.

NM
By

Nathaniel Montgomery

Elena Vance is a freelance film critic and screenwriter based in London, sharing her passion for cinema through detailed analysis.

Modern Reel Review

Type to search articles.